Third-generation smallpox vaccines: challenges in the absence of clinical smallpox.
Smallpox, a disease caused by variola virus, is estimated to have killed hundreds of millions to billions of people before it was certified as eradicated in 1980. However, there has been renewed interest in smallpox vaccine development due in part to zoonotic poxvirus infections and the possibility of a re-emergence of smallpox, as well as the fact that first-generation smallpox vaccines are associated with relatively rare, but severe, adverse reactions in some vaccinees. An understanding of the immune mechanisms of vaccine protection and the use of suitable animal models for vaccine efficacy assessment are paramount to the development of safer and effective smallpox vaccines. This article focuses on studies aimed at understanding the immune responses elicited by vaccinia virus and the various animal models that can be used to evaluate smallpox vaccine efficacy. Harnessing this information is necessary to assess the effectiveness and potential usefulness of new-generation smallpox vaccines.
Meseda
Clement A
CA
Center for Biologics Evaluation & Research, USFDA, Rockville, MD 20852, USA. clement.meseda@fda.hhs.gov
Weir
Jerry P
JP
D000818:Animals; D000914:Antibodies, Viral / Q000097:blood; D004195:Disease Models, Animal; D006801:Humans; D051379:Mice; D018155:Orthopoxvirus / Q000472:pathogenicity*; D011213:Poxviridae Infections / Q000276:immunology* / Q000517:prevention & control* / Q000821:virology; D011817:Rabbits; D012899:Smallpox / Q000276:immunology / Q000517:prevention & control*; D012900:Smallpox Vaccine / Q000008:administration & dosage / Q000009:adverse effects* / Q000276:immunology*; D014611:Vaccination; D014616:Vaccinia virus / Q000276:immunology; D012901:Variola virus / Q000276:immunology
D000914:Antibodies, Viral; D012900:Smallpox Vaccine